<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jacobson, Anne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Böhm, Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ONTARGET: Treatment Nonadherence Rapidly Increases CV Event Risk</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-26</style></pages><abstract><style  face="normal" font="default" size="100%">Patients who are at high risk for cardiovascular events face a vicious cycle in which treatment nonadherence increases event rates while events themselves reinforce nonadherence, according to new findings from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET].</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>